Gentium Submits New Drug Application to FDA

Gentium S.p.A.

today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for Defibrotide for the treatment of hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem-cell transplantation.